PCMA Blog
Shining the Light on Prescription Drug Wholesalers: Pillar Five in the Path to Patient Affordability
When costs rise, everyone points fingers. Transparency helps identify facts. Three companies control 97% of the U.S. drug wholesale market,
Are You Smarter Than a PBM Headline?
You’ve seen the headlines. You’ve heard the debate. Now it’s time for a pop quiz. How much do you really
New DOL E-Disclosure Proposal Will Save Billions, Underscores How PBM Rule Undermines Goal of Reducing Needless Regulation
In early 2025, President Trump issued an Executive Order that required federal agencies to cut 10 regulations for every new
What Is a PBM?
How PBMs Are Leading the Charge on Transparent Information for Patients… With Landmark PBM Reform Enacted, Getting Implementation Right Matters…
How the Future of GLP-1 Affordability Depends on Competition
By Amanda Frost, PhD Vice President, Research, PCMA There is no shortage of opinions these days about GLP-1 prescription drugs:
From Flashy Ads to Expensive Drugs: 5 Things You Need to Know About Misleading Drug Advertisements
By Amanda Frost, PhD Vice President, Research, PCMA I don’t watch much television these days, but when I do, I can be assured of
PCMA Urges HHS, DOL, and Treasury to Support Patient Access and Preserve Flexibility in New Fertility Benefits Rule
By Dalita Collins, Director, Policy On July 13, 2026, PCMA submitted comments to the Departments of Health and Human Services (HHS), Labor
Accelerating Biosimilar Competition for Patients: Pillar Four of the Path to Patient Affordability
Choices give power to consumers, who can find value and use their purchasing decisions to make companies compete. In health